NEK2 and cancer: Since Nek2 interacts with MAD2 [110] and SAC has emerged as a promising target for cancer therapy [111], modulation of NEK2 activity and/or MAD2 AS could be exploited therapeutically in TGCTs patients displaying resistance to cisplatin-based chemotherapy.